Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations

摘要

Patients with acquired resistance to first-generation EGFR TKIs, including those with the T790M mutation, may still respond to EGFR-targeted therapy.